OPKO Health, Inc. Accumulated Other Comprehensive Income
OPKO Health, Inc. (OPK) had Accumulated Other Comprehensive Income of -$28.39 million as of 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent › Accumulated Other Comprehensive Income (Loss), Net of Tax
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-28
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$28.39M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$27.49M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$21.02M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$25.47M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$28.39M 10-Q/A · filed 2026-08-28 |
| 2026-03-31 | -$27.49M 10-Q/A · filed 2026-08-28 |
| 2025-12-31 | -$21.02M 10-Q/A · filed 2026-08-28 |
| 2025-09-30 | -$25.47M 10-Q · filed 2025-10-29 |
| 2025-06-30 | -$24.73M 10-Q · filed 2025-07-31 |
| 2025-03-31 | -$45.01M 10-Q · filed 2025-05-01 |
| 2024-12-31 | -$56.13M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$39.61M 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$46.65M 10-Q · filed 2024-08-07 |
| 2024-03-31 | -$45.20M 10-Q · filed 2024-05-07 |
| 2023-12-31 | -$38.03M 10-K · filed 2025-03-03 |
| 2023-09-30 | -$46.49M 10-Q · filed 2023-11-06 |
| 2023-06-30 | -$36.94M 10-Q · filed 2023-08-03 |
| 2023-03-31 | -$37.61M 10-Q · filed 2023-05-03 |
| 2022-12-31 | -$43.32M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$58.03M 10-Q · filed 2022-11-08 |
| 2022-06-30 | -$49.17M 10-Q · filed 2022-08-04 |
| 2022-03-31 | -$31.41M 10-Q · filed 2022-05-09 |
| 2021-12-31 | -$30.50M 10-K · filed 2023-02-27 |
| 2021-09-30 | -$19.92M 10-Q · filed 2021-10-28 |
| 2021-06-30 | -$9.93M 10-Q · filed 2021-07-29 |
| 2021-03-31 | -$13.29M 10-Q · filed 2021-04-28 |
| 2020-12-31 | -$4.22M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$17.45M 10-Q · filed 2020-10-29 |
| 2020-06-30 | -$25.75M 10-Q · filed 2020-07-31 |
| 2020-03-31 | -$30.19M 10-Q · filed 2020-05-06 |
| 2019-12-31 | -$22.07M 10-K · filed 2021-02-18 |
| 2019-09-30 | -$28.77M 10-Q · filed 2019-11-05 |
| 2019-06-30 | -$20.35M 10-Q · filed 2019-08-07 |
| 2019-03-31 | -$23.23M 10-Q · filed 2019-05-08 |
| 2018-12-31 | -$20.13M 10-K · filed 2020-03-02 |
| 2018-09-30 | -$13.14M 10-Q · filed 2018-11-09 |
| 2018-06-30 | -$13.00M 10-Q · filed 2018-08-07 |
| 2018-03-31 | -$539.00K 10-Q · filed 2018-05-08 |
| 2017-12-31 | -$528.00K 10-K · filed 2019-03-01 |
| 2017-09-30 | -$5.42M 10-Q · filed 2017-11-08 |
| 2017-06-30 | -$14.07M 10-Q · filed 2017-08-08 |
| 2017-03-31 | -$24.95M 10-Q · filed 2017-05-10 |
| 2016-12-31 | -$27.01M 8-K · filed 2019-01-29 |
| 2016-09-30 | -$16.28M 10-Q · filed 2016-11-07 |
| 2016-06-30 | -$23.43M 10-Q · filed 2016-08-08 |
| 2016-03-31 | -$17.11M 10-Q · filed 2016-05-09 |
| 2015-12-31 | -$22.54M 10-K · filed 2017-03-01 |
| 2015-09-30 | -$20.99M 10-Q · filed 2015-11-09 |
| 2015-06-30 | -$18.88M 10-Q · filed 2015-08-05 |
| 2015-03-31 | -$17.50M 10-Q · filed 2015-05-11 |
| 2014-12-31 | -$12.39M 10-K · filed 2016-02-29 |
| 2014-09-30 | -$8.70M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $304.00K 10-Q · filed 2014-08-11 |
| 2014-03-31 | $1.40M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $3.42M 10-K · filed 2016-02-29 |
| 2013-09-30 | $3.24M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $2.83M 10-Q · filed 2013-08-09 |
| 2013-03-31 | $8.09M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $7.36M 10-K · filed 2015-02-27 |
| 2012-09-30 | $9.00M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $6.72M 10-Q · filed 2012-08-09 |
| 2012-03-31 | $2.41M 10-Q · filed 2012-05-10 |
| 2011-12-31 | $907.00K 10-K · filed 2013-03-18 |
| 2011-09-30 | $434.00K 10-Q · filed 2011-11-09 |
| 2011-06-30 | $3.16M 10-Q · filed 2011-08-08 |
| 2010-12-31 | $2.92M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |